Athira Pharma Inc. (NASDAQ: ATHA) kicked off on January 24, 2023, at the price of $3.48, up 6.10% from the previous trading day. During the day, the shares moved up to $3.87 and dropped to $3.43 before settling in for the closing price of $3.44. Over the past 52 weeks, ATHA has traded in a range of $2.53-$14.22.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
While this was happening, its average annual earnings per share was recorded -141.90%. With a float of $35.89 million, this company’s outstanding shares have now reached $37.82 million.
Considering the fact that the conglomerate employs 34 people, you should pay attention to its efficiency factor.
Athira Pharma Inc. (ATHA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Athira Pharma Inc. is 1.10%, while institutional ownership is 64.50%. The most recent insider transaction that took place on Dec 28, was worth 142,250. In this transaction Chief Financial Officer of this company bought 50,000 shares at a rate of $2.85, taking the stock ownership to the 159,930 shares. Before that another transaction happened on Dec 02, when Company’s Director bought 30,000 for $3.29, making the entire transaction worth $98,700. This insider now owns 38,315 shares in total.
Athira Pharma Inc. (ATHA) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 6/29/2022, the organization reported -$0.65 earnings per share (EPS), lower than consensus estimate (set at -$0.64) by -$0.01. This company achieved a return on equity of -18.43. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.67 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -141.90% per share during the next fiscal year.
Athira Pharma Inc. (NASDAQ: ATHA) Trading Performance Indicators
Take a look at Athira Pharma Inc.’s (ATHA) current performance indicators. Last quarter, stock had a quick ratio of 22.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.10, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -2.97 in one year’s time.
Technical Analysis of Athira Pharma Inc. (ATHA)
Compared to the last year’s volume of 0.5 million, its volume of 0.88 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 44.31%. Additionally, its Average True Range was 0.25.
During the past 100 days, Athira Pharma Inc.’s (ATHA) raw stochastic average was set at 72.44%, which indicates a significant increase from 58.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.51% in the past 14 days, which was lower than the 68.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.23, while its 200-day Moving Average is $4.94. Nevertheless, the first resistance level for the watch stands at $3.87 in the near term. At $4.09, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.31. If the price goes on to break the first support level at $3.43, it is likely to go to the next support level at $3.21. Now, if the price goes above the second support level, the third support stands at $2.99.
Athira Pharma Inc. (NASDAQ: ATHA) Key Stats
The company with the Market Capitalisation of 133.33 million has total of 37,829K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -54,850 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -20,189 K.